Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Ligand Pharmaceuticals / Equity Bottom-Up

<ul><li>Ligand Pharmaceuticals holds a portfolio of revenue, royalty and milestone generating assets that have been vetted by its internal investment team.</li><li>Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.</li><li>It targets late-stage and commercial income-producing assets when making investments.</li></ul>

Ligand Pharmaceuticals holds a portfolio of revenue, royalty and milestone generating assets that have been vetted by its internal investment team.Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.It targets late-stage and commercial income-producing assets when making investments.

LGND: 1Q:26 Results Highlight Breadth of Portfolio

<ul><li>Zacks Small-Cap Research Note for Ligand Pharmaceuticals, Inc. (LGND)</li></ul>

Zacks Small-Cap Research Note for Ligand Pharmaceuticals, Inc. (LGND)

<ul><li>Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment team.</li><li>Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.</li><li>It targets late-stage and commercial income-producing assets when making investments.</li></ul>

Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment team.Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.It targets late-stage and commercial income-producing assets when making investments.

United States

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors.  These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ligand Pharmaceuticals (LGND US)

LGND: 1Q:26 Results Highlight Breadth of Portfolio

Ligand Pharmaceuticals holds a portfolio of revenue, royalty and milestone generating assets that have been vetted by its internal investment...

Zacks Small Cap Research

LGND: XOMA Buy Adds 100+ Assets

Zacks Small-Cap Research Note for Ligand Pharmaceuticals, Inc. (LGND)

Zacks Small Cap Research

LGND: 2025 Results & Focus on Qtorin

Ligand Pharmaceuticals holds a portfolio of revenue, royalty and milestone generating assets that have been vetted by its internal investment...

Zacks Small Cap Research

LGND: New Year Program Updates

Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment...

Zacks Small Cap Research

LGND: 2025 Analyst Day

Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)